Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Dousson, FR

Christophe Dousson, Lannion FR

Patent application numberDescriptionPublished
20090119392METHOD FOR MANAGING DECISIONS, METHOD FOR CONSTRUCTING A DECISION TREE, CENTRAL MANAGER, INTERMEDIATE MANAGER, TERMINAL AND CORRESPONDING COMPUTER PROGRAM PRODUCTS - A method is provided for managing decisions between a central manager and at least one terminal in an architecture of networks distributed and prioritized according to N levels, with N≧2. The central manager is included in a level of rank N. The terminal is included in a level of rank 1. The method includes a step of distributing a decision tree constructed by the central manager and supported by the architecture.05-07-2009

Cyril Dousson, Canet FR

Patent application numberDescriptionPublished
20080213217Enantiomerically pure phosphoindoles as HIV inhibitors - 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.09-04-2008
20090060866PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I′, II′, I″, II″, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.03-05-2009
20090060867PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI - Provided herein are phosphadiazine polymerase inhibitor, for example, of Formula III, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.03-05-2009
20090060872PHOSPHADIAZINE HCV POLYMERASE INHIBITORS V - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas V, V′, I″, II″, or Va, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.03-05-2009
20090081158PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas IV, IV′, I″, II″, or IVa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.03-26-2009
20100233123PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS - Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host infected with HCV.09-16-2010

Patent applications by Cyril Dousson, Canet FR

Cyril Dousson, Montpellier FR

Patent application numberDescriptionPublished
20090163444PHOSPHO-INDOLES AS HIV INHIBITORS - 3-phosphoindole compounds for the treatment of retroviral infections, and particularly for HIV, are described. Also included are compositions comprising the 3-phosphoindole derivatives alone or in combination with one or more other anti-retroviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.06-25-2009

Cyril B. Dousson, Canet FR

Patent application numberDescriptionPublished
201101508275,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS - Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.06-23-2011